Telix Pharmaceuticals falls on dilution risks in $1.65bn ITM deal
Shares of Telix Pharmaceuticals fell as much as 10.2% to A$16.030, their biggest intraday percentage fall since Aug. 28, 2025. The biopharma company agreed to buy Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis. "Sharp negative reaction in Telix reflects the dilution concerns of traders," said Tim Waterer, chief market analyst at KCM Trade, adding that Telix is issuing a significant number of new shares to fund the deal, which will leave existing shareholders owning a smaller slice of the combined entity. The stock is up over 40% this
030, their biggest intraday percentage drop since August 28, 2025. The stock hit its lowest level since September 14. 65 billion on a cash- and debt-free basis. "Sharp negative reaction in Telix reflects the dilution concerns of traders," Tim Waterer, chief market analyst at KCM Trade, said.
Waterer said TLX is issuing a significant number of new shares to help fund the deal, which will leave existing shareholders with a smaller slice of the combined entity. The stock is up over 40% this year, including the day's move.